Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
(BQ) Part 2 book “Botulinum toxins in clinical aesthetic practice” has contents: The different botulinum toxins from around the world available for clinical use, botulinum toxin used in conjunction with other injectables and devices for cosmetic purposes, beyond the obvious - Beauty optimization with botulinum toxin, and other contents. | 6 The different botulinum toxins from around the world available for clinical use Andy Pickett INTRODUCTION Botulinum toxin (BoNT) has been one of the most successful products ever developed in the world of pharmaceuticals. Since the first publication from Alan Scott in the 1970s1 on the potential medical application of the molecule, use of BoNT products in both therapeutic and aesthetic treatments has grown year-on-year. Following the first licensure of the products in the late 1980s, nearly 30 years ago, their use has widened and expanded throughout the world. The applicability of BoNT to bringing real benefit to patients in a multitude of ways cannot be overstated. Although not life-saving, the BoNT products have clearly improved the quality of life of many people and have become a mainstay of many key and often untreatable areas of neurology, urology, and pain, as well as the aesthetic uses they have become equally famous for. New uses are regularly identified, especially in areas such as dermatology and these are almost universally shown to be of important clinical value for patient treatment. The true size of the BoNT market is difficult to determine. Accurate data are available for therapeutic uses, but no equivalent data exist for the aesthetic marketplace. Estimates in the order of over $3 billion are currently available,2 growing many times over the next decade.3 However, the potential financial scale could be described as limitless, given the number of new uses emerging and the ever-growing routine use of the products across such a wide range of applications. Perhaps the only restriction on this growth is the time taken and data required for the official registration of each new indication with each country’s regulatory authority. There were initially two commercial BoNT products—Oculinum® and Dysport® (otherwise known as AbobotulinumtoxinA [AboBTX-A]). Oculinum® was pioneered by Alan Scott through his company Oculinum Inc., using the results he had .
